<code id='B66A29D161'></code><style id='B66A29D161'></style>
    • <acronym id='B66A29D161'></acronym>
      <center id='B66A29D161'><center id='B66A29D161'><tfoot id='B66A29D161'></tfoot></center><abbr id='B66A29D161'><dir id='B66A29D161'><tfoot id='B66A29D161'></tfoot><noframes id='B66A29D161'>

    • <optgroup id='B66A29D161'><strike id='B66A29D161'><sup id='B66A29D161'></sup></strike><code id='B66A29D161'></code></optgroup>
        1. <b id='B66A29D161'><label id='B66A29D161'><select id='B66A29D161'><dt id='B66A29D161'><span id='B66A29D161'></span></dt></select></label></b><u id='B66A29D161'></u>
          <i id='B66A29D161'><strike id='B66A29D161'><tt id='B66A29D161'><pre id='B66A29D161'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          entertainment

          author:focus    - browse:2428
          Dozens of sickle cells in a whirlpool — coverage from STAT
          Adobe

          Nearly a decade ago, consultants delivered to Rodger Novak a kind of Sears catalog of human malady: 200 pages, listing dozens of different diseases, each annotated with — from a business standpoint — their best and worst attributes. 

          The document was supposed to help Novak, then the chief executive of CRISPR Therapeutics, navigate a pressing quandary. His company, along with two others, were founded to commercialize the new revolutionary gene-editing tool CRISPR-Cas9, which promised to cure numerous genetic diseases. But which should they target first? What was the best proof-of-concept?

          advertisement

          “We looked at anything and everything,” said Novak, who stepped down as CEO in 2017 but remained on the board until this year. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia